Michael Gibson votes with FDA panel to limit immunotherapy indication
The panel determined that allowing the wider indication would put patients at risk for adverse reactions from the two immunotherapies but without the added benefit in survival.
Tae Kon Kim receives V Foundation grant for MDS drug research
The V Foundation for Cancer Research has awarded a $600,000 grant to Tae Kon Kim, MD, PhD, assistant professor of Medicine (Hematology and Oncology). Kim and colleagues will study whether this protein hinders the ability of the immune system to fight MDS and whether it can be blocked to treat MDS.
Eng named VICC associate director of Strategic Relations and Research Partnerships
In this new position Cathy Eng, MD (Hematology and Oncology), the David H. Johnson Professor of Surgical and Medical Oncology, will elevate Vanderbilt-Ingram’s profile locally, regionally, nationally and internationally through stakeholder engagement, programmatic development and targeted marketing.
‘Off-the-shelf’ CAR T therapy shows promise for relapsed/refractory multiple myeloma
Interim results are promising from on ongoing phase 1 clinical trial testing an allogeneic or “off-the-shelf” chimeric antigen receptor Tcell (CAR T) therapy for patients with multiple myeloma who have not responded to existing treatments or who have relapsed.
Study shows cancer vaccine blocks tumor progression at early lesion stage
A cancer vaccine that had little success in clinical trials for patients with advanced tumors could potentially have efficacy if administered earlier in the treatment cycle, according to a study from Vanderbilt researchers.
VUMC physician-scientists recognized for extending veterans’ lung cancer screening
Jennifer Lewis, MD, MPH, and Lucy Spalluto, MD, MPH, are the recipients of the 2024 VAQS Team Award for work they began in 2017.
International trial introduces another curative option for sickle cell disease
The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.
International overview of colorectal cancer provides multidisciplinary perspective of clinical advances
Cathy Eng, MD (Hematology and Oncology), is corresponding author of a paper published last week in The Lancet that provides an overview on treatment advances, clinical trials, incidence trends and ongoing challenges related to colorectal cancer, the third most diagnosed cancer in the world.
Study seeks to evaluate military exposures on veterans’ lung cancer risk
A prospective cohort of veterans including those with military toxic exposures, such as burn pits, will be screened annually with low-dose chest CT to detect lung cancer and other disease early.
Clinical trial shows efficacy for atezolizumab combined with carboplatin
Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers such as PD-L1 that are used to predict response are mediocre at best.